ArticleJournal of clinical medicine2020
Antimycobacterial Effects of Everolimus in a Human Granuloma Model.
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Pooled it
- The Effects of Oral Liposomal Glutathione and In Vitro Everolimus in Altering the Immune Responses againstBiomolecular concepts · 2021Trial
- mTORC1 inhibitors rapamycin and everolimus as host-directed therapy for tuberculosis.Infection and immunity · 2026Article
- Recent advances in tuberculosis treatment: Towards shorter, safer, and more effective therapies.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Review
- Autophagy in tuberculosis: advances, translational gaps, and the promise of host-directed therapies.Frontiers in cellular and infection microbiology · 2026Review
- Host-directed therapeutic targets in macrophages and their ligands against mycobacteria tuberculosis.Infection and immunity · 2025Review
- Host-directed therapy for tuberculosis.European journal of medical research · 2025Review
- Inducible antibacterial responses in macrophages.Nature reviews. Immunology · 2025Review
- Autophagy in mycobacterial infections: molecular mechanisms, host-pathogen interactions, and therapeutic opportunities.Frontiers in cellular and infection microbiology · 2025Review
- The Role of mTOR inBiomedicines · 2024Review
- Review
- Review
- Pathogenicity of Type I Interferons inInternational journal of molecular sciences · 2023Review
- Evaluation of Everolimus Activity againstAntibiotics (Basel, Switzerland) · 2023Article
- Macrophage targeted polymeric curcumin nanoparticles limit intracellular survival ofFrontiers in immunology · 2023Article
- Different modalities of host cell death and their impact onAmerican journal of physiology. Cell physiology · 2022Review
- Surveying the Epigenetic Landscape of Tuberculosis in Alveolar Macrophages.Infection and immunity · 2022Review
- Modulating macrophage function to reinforce host innate resistance againstFrontiers in immunology · 2022Review
- Mycoplasma bovis subverts autophagy to promote intracellular replication in bovine mammary epithelial cells cultured in vitro.Veterinary research · 2021Article
- Review of the Effectiveness of Various Adjuvant Therapies in TreatingInfectious disease reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.